GS-4774 + tenofovir disoproxil fumarate

GS-4774 + tenofovir disoproxil fumarate is a **combination therapy** for chronic hepatitis B infection comprising **GS-4774**, a yeast-based therapeutic vaccine expressing HBV antigens designed to activate HBV-specific T cell immune responses, and **tenofovir disoproxil fumarate**, a nucleotide analogue antiviral agent that inhibits HBV replication. GS-4774 attempts to stimulate the host's immune system—particularly CD8+ T cells—by increasing production of cytokines such as IFNγ, TNF, and IL2 in response to HBV antigens. Tenofovir acts through direct inhibition of viral DNA polymerase as a small molecule antiviral. The goal of the combination is to both suppress HBV replication and enhance immune-mediated clearance of infected cells, potentially improving cure rates versus antiviral monotherapy.

Brand names

Viread (for tenofovir disoproxil fumarate)

Other names

GS-4774 + TDFGS-4774 plus tenofovirGS4774 plus tenofovirGS 4774 plus tenofovirGS-4774 and tenofovirGS4774 and tenofovirGS 4774 and tenofovir